The Street’s Key Stock Analysts Research Reports


Daily HeffX-LTN reviews dozens of  the Street’s Key analysts research reports to ID new trading and investing ideas for HeffX-LTN readers. Some reports cover stocks to buy, and others cover stocks to sell or avoid.

Below is a list of The Street’s Key analysts outlook for Key issues for Tuesday as follows:

Antares Pharma Inc. (NASDAQ:ATRS) started as Outperform and assigned a 7 price target at Cowen. The stock was indicated up 2.5% at $3.30, in a 52-week range of $1.99 to $3.99 and with a $507 million market cap.

Brunswick Corp. (NYSE:BC) was raised to Overweight from Neutral at JPMorgan.

Builders FirstSource Inc. (NASDAQ:BLDR) was started as Neutral at Buckingham Research.

Capstead Mortgage Corp. (NYSE:CMO) was raised to Market Perform from Underperform and the target price was raised to 8.50 from 7.00 at Keefe Bruyette & Woods.

Cboe Global Markets Inc. (BATS:CBOE) was raised to Overweight from Neutral at MKM Partners.

Foot Locker Inc. (NYSE:FL) was reiterated as Outperform and the price target was raised to 70 from 63 at Credit Suisse. Wedbush also reiterated its Outperform rating and raised its target to 67 from 63 with above-consensus FY 2019 estimates heading into results on 1 March.

Marathon Oil Corp. (NYSE:MRO) was maintained as Buy but the price target was lowered to 22 from 25 at Argus. The independent research firm sees Marathon with a positive view of its focus on short-cycle unconventional North American Crude Oil, Nat Gas and NGL production and noted that it has divested $4-B of non-core assets over the past 2 years.

Stay tuned…

The following two tabs change content below.

Paul Ebeling

Paul A. Ebeling, polymath, excels in diverse fields of knowledge. Pattern Recognition Analyst in Equities, Commodities and Foreign Exchange and author of “The Red Roadmaster’s Technical Report” on the US Major Market Indices™, a highly regarded, weekly financial market letter, he is also a philosopher, issuing insights on a wide range of subjects to a following of over 250,000 cohorts. An international audience of opinion makers, business leaders, and global organizations recognizes Ebeling as an expert.

Latest posts by Paul Ebeling (see all)

You must be logged in to post comments :